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Luminal B breast cancer subtype 
displays a dicotomic epigenetic pattern
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Abstract 
Luminal B breast tumors have aggressive clinical and biological features, and constitute the most heterogeneous 
molecular subtype, both clinically and molecularly. Unfortunately, the immunohistochemistry correlate of the luminal 
B subtype remains still imprecise, and it has now become of paramount importance to define a classification scheme 
capable of segregating luminal tumors into clinically meaningful subgroups that may be used clinically to guide 
patient management. With the aim of unraveling the DNA methylation profiles of the luminal subtypes currently 
being most used in the clinical setting, we have quantified the DNA methylation level of 27,578 CpG sites in 17 lumi‑
nal B (ER+, Ki67 ≥ 20 % or PgR < 20 % and HER2−), 8 luminal A (ER+ and Ki67 > 20 %) and 4 luminal B‑HER2+ (ER+ 
and HER2+) breast cancer samples by using the Illumina Infinium methylation microarray approach. Unsupervised 
hierarchical clustering revealed that DNA methylation stratifies luminal B samples in two categories with differing 
epigenetic and clinical features. One subgroup of luminal B samples showed a methylator phenotype and clustered 
with the lumB‑HER tumors, while the other showed less methylated events, clustered with the luminal A. A 3 CpG 
marker panel capable of discriminating methylator versus non‑methylator luminal B samples was identified and 
further validated in an independent cohort of patients. Our results provide evidence that DNA methylation and, more 
specifically, a panel of 3 CpG markers, enables the stratification of luminal B samples in two categories with differing 
epigenetic and clinical features and support the utilization of this panel for therapeutic stratification of patients with 
luminal breast cancer.
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Background
Breast cancer (BC) is a complex and heterogeneous 
disease which includes several subtypes with different 
molecular and clinical characteristics. A major mile-
stone on the classification of the breast carcinomas 
is the so called “intrinsic classification”, which divides 
breast tumors into at least five clinically and biologi-
cally relevant intrinsic molecular subtypes based on 
genome-wide expression analyses: luminal A, luminal 
B, HER2-enriched, basal-like, and normal breast-like. In 
this respect, the luminal B subtype constitutes the most 
heterogeneous group, both clinically and molecularly. In 
fact, although many of the Luminal B tumors are ER+/
HER2−/high Ki-67, expression profiles also classify the 
ER+/HER2+ tumors as luminal B and these patients 
receive a different therapy regimen (that incorporates 
targeted anti-HER2 therapy) compared to other luminal 
B BC subtypes (Cancer Genome Atlas Network 2012). 
With respect to the HER2-negative luminal B tumors, 
they are inherently more aggressive than the luminal A 
and they require a more aggressive therapy. However, 
although recent studies have reported that some of the 
HER2-negative tumors could benefit from anti-HER2 
therapy treatment (Pogue-Geile et  al. 2013), luminal B 
tumors are generally treated with a combination of endo-
crine therapy and chemotherapy, though this approach 
is not always effective. In view of the clinical/molecular 
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heterogeneity of the luminal B tumors, the 12th St. Gal-
len International Expert Consensus proposed a new 
classification system that was further updated in the 
13th Consensus by which the luminal BC subtypes were 
separated into three groups based on the ER, progester-
one (PgR), HER2 and Ki-67 status—(1) luminal A-like 
tumors are ER-positive and HER2-negative with low 
Ki-67 expression (<20 %) and high PgR levels (≥20 %); (2) 
luminal B-like (HER2-negative) tumors are ER-positive 
and HER2-negative with high Ki-67 expression (≥20 %) 
or with low PgR levels (<20 %); and (3) luminal B-HER2 
tumors are ER-positive and HER2-positive regardless 
PgR or Ki-67 expression. Luminal A disease is stated to 
require only endocrine therapy, whereas in luminal B 
disease, chemotherapy should be also considered. Thus, 
one major challenge in the management of luminal BCs 
is to discriminate those patients that would benefit from 
cytotoxic drugs or anti-targeted therapy from those that 
would not.
The epigenetic transcriptional regulation by DNA 
methylation and modifications of histones is closely asso-
ciated with corresponding gene expression in human 
genome. In addition, DNA methylation profiles have 
shown to be perturbed in a number of human diseases, 
including cancer (Esteller 2008; Jones and Takai 2001; 
Keshet et  al. 2006; Suzuki and Bird 2008). Further-
more, many studies suggest that epigenetic changes are 
involved in the earliest phases of tumorigenesis, con-
tributing to the overexpression of oncogenes and down-
regulation of tumor suppressor genes. Analogously to 
transcriptomic profiling, DNA methylation profiling has 
been used to molecularly classify a number of human 
malignancies as well as to monitor cancer progression 
based on tumor-specific methylation signatures (Orlando 
and Brown 2009).
In BC, specific aberrant methylation patterns have been 
associated with different BC histologic and molecular 
subtypes (Dedeurwaerder et al. 2011; Bediaga et al. 2010; 
Holm et  al. 2010; Stefansson et  al. 2015; Cornen et  al. 
2014; Li et al. 2014; Kamalakaran et al. 2011). Particularly, 
ER−/luminal breast tumors have shown to be character-
ized by a higher frequency of DNA methylation com-
pared to ER−/basal-like tumors; and within the luminal 
subgroup, luminal A displayed a substantially lower pro-
portion of DNA methylation marks than the luminal B, 
although they were quite heterogeneous with regard to 
the methylation status (Stefansson et  al. 2015). Taken 
all together, these data suggest that DNA methylation 
profiles may play an important role in the development 
and progression of distinct breast subtypes. However, 
most of the epigenome-wide studies published so far 
are performed on mRNA based subtypes instead of on 
immunohistochemistry (IHC) based BC subtypes, even if 
the later are the ones often used to guide the best deci-
sion-making in patient treatment as a part of the routine 
work-up of BC. Therefore, we believe that epigenetically 
profiling luminal (ER+) tumors that have been stratified 
with the latest IHC based classification scheme will led 
to a continuous refinement of the molecular classification 
of the BC and this could open up potentials for identify-
ing and developing appropriate therapies for these tumor 
subtypes that sometime defies effective treatment.
Methods
Samples
A total of 28 luminal subtype BC samples as well as the 
adjacent tissue samples of eight were obtained from the 
Pathology Services of the Hospital Universitario Araba-
Txagorritxu (Vitoria-Gasteiz), Oncologikoa (Donostia) 
and Hospital Universitario Donostia (Donostia), all of 
them from the Basque Country, in the north of Spain. All 
breast specimens were reviewed by experienced patholo-
gists. The inclusion criteria were availability of DNA 
from fresh frozen tumor tissue, tumor size between 2 
and 3  cm, histological grade between 2 and 3, and, fol-
lowing the classification proposed in the 13th St Gallen 
International Breast Cancer Conference in 2013, ER+, 
any PgR, any Ki-67 and HER2-positive for the luminal 
B-HER2 subtype; ER+, PgR  ≥  20  %, Ki67  <  20  % and 
HER2-negative for the Luminal A and ER+, Ki67 ≥ 20 % 
or PgR  <  20  % and HER2-negative for the Luminal B. 
Eligible patients were postmenopausal women with his-
tologically proven invasive ductal breast carcinoma. 
Additional data such as nodal involvement were also reg-
istered. Ethical approval for the study was obtained from 
the Txagorritxu Hospital ethic committee (No. 2010-064) 
and samples were collected according to clinicopatholog-
ical protocols.
Genomic DNA was extracted using a DNeasy Blood & 
Tissue Kit (Qiagen, Valencia, USA), and DNA was bisul-
phite treated using the EZ DNA methylation Kit™ (Zymo 
Research, USA) following the manufacturer’s protocol.
DNA methylation profiling
The Infinium HumanMethylation27K (Illumina Inc., 
CA, USA) was used to assess the methylation profile 
of 28 luminal subtype BCs, as well as 8 adjacent tissue. 
The assay interrogates the methylation level of 27,578 
CpG sites spanning 14,495 protein coding gene promot-
ers and 110 microRNA gene promoters at single-nucle-
otide resolution. All data were packaged and deposited 
in NCBI’s Gene Expression Omnibus (GEO) and are 
accessible through GEO Series accession number [GEO: 
GSE73808].
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Computational analysis of the methylation levels
The Illumina Infinium methylation microarray data was 
processed using the Bioconductor lumi package (Du 
et al. 2010). First, data were extracted with the Genome 
Studio™ Methylation Module software. The data went 
through a quality control (QC) step. The data passing 
QC step was preprocessed using a color balance adjust-
ment of methylated and unmethylated probe intensities 
between two color channels using a smooth quantile 
normalization method. The methylated and unmethyl-
ated probe intensities were then background adjusted 
and normalized using the Quantile method. Differential 
methylation values were detected by applying the Bayes-
ian moderated t test on the normalized matrix of inten-
sity values (M values) (Du et  al. 2010; Smyth 2005). In 
order to recognize CpG sited with both high statistical 
significance and strong biological effects, we identified 
differentially methylated CpG-sites based on the follow-
ing criteria: false-discovery-rate-adjusted (FDR-adjusted) 
p value <0.05 and an absolute DNA methylation differ-
ences >than 0.2. Cluster analysis of the epigenome-wide 
data was performed using unsupervised hierarchical 
clustering with the Ward. D2 linkage and Manhattan 
distance as a measure of similarity as described in Ste-
fansson et  al. (Stefansson et  al. 2015) (heatmap.2 func-
tion implemented in the gplot package for R) on the 
1264 CpGs found differentially methylated between 
breast tumors and normal breast samples (Additional 
file 1: Table S1). We next used the pvclust package in R 
to define statistically significant tumor clusters as those 
showing an AU (approximately unbiased) p value >90 (at 
least five members). Lists of aberrantly methylated CpGs 
were further analyzed in order to test for differences in 
the counting of CpGs by categories reflecting function-
ally relevant sequences: (1) promoter regions, those 
located proximal to the transcription start site (TSS) (i.e. 
CpG’s located within 200  bp of the TSS or within the 
5′UTR/1stExon); (2) TSS1500, those located more dis-
tantly from the TSS lying within the interval from 200 to 
1500  bp upstream of the TSS site; (3) gene body, those 
found within the gene body (excluding the 1st Exon) and 
(4) 3′UTR, those located at the 3′UTR. In addition, CpGs 
were classified as into three different groups, i.e. those 
found within (1) CpG islands, (2) CpG shores and (3) 
CpG poor regions. Continuous variables were compared 
by use of the Mann–Whitney U test and distributions of 
categorical variables by Chi squared contingency tests. 
Finally, the predictive power, which measures the ability 
of a single site to differentiate the samples in each clus-
ter, was evaluated using the area under the ROC curve 
(AUC) associated to the site, where an AUC of 1 means 
that the methylation level of that site perfectly separates 
the samples into the two clusters.
Results
Luminal breast cancer subtypes display distinct 
clinicopathologic characteristics
With the aim of assessing the epigenetic heterogeneity 
among BC subtypes with similar histologically character-
istics, only tumor size between 2 and 3 cm and histologi-
cal grade between 2 and 3 were included in the current 
study. Thus, as expected, we did not find any statistical 
difference in histological grade and tumor size, and nei-
ther did we in the nodule involvement. Patient character-
istics are presented in Table 1.
Unsupervised clustering of the luminal subtype samples 
based on DNA methylation profiling
Unsupervised hierarchical clustering based on the list of 
1264 differently methylated CpGs between breast tumors 
and normal breast (Additional file 1: Table S1) identified 
two significant tumors groups (significant at AU > 95 %; 
by the pvclust method) (Fig.  1). This classification was 
compared to the BC luminal subtypes as previously 
determined by histological profiling. Cluster II (CII) 
grouped the whole set of luminal B-HER2 and 31.25 % of 
the luminal B phenotypes. These tumors showed exten-
sive DNA methylation of CpGs implying that they have 
acquired a methylator phenotype. On the other hand, 
cluster I (CI) contained the entire set of luminal A phe-
notypes plus 62.5 % of the luminal B tumors. Overall this 
cluster showed a lower degree of methylation. When we 
compared the clinical and histological characteristics 
between the CI and CII, we found some statistically sig-
nificant differences. Overall, luminal tumors in CI were 
smaller (p = 0.01), showed a lower Ki-67 levels (p = 0.01) 
and probably better outcome (the only two patients with 
relapsed disease were in CII). Specifically, when only the 
luminal B samples were selected, we found that luminal B 
samples fitting in CI were also smaller (p = 0.01) and had 
a better outcome.
Identification of cluster specific DNA methylation profiles
In order to identify CpGs with highly significant clus-
ter specific changes, stringent cut-offs (adjusted p value 
<0.05 and ∆b  >  0.20) were set for methylation level 
changes relative to controls for each cluster. Distinct 
CpG loci groups containing no known SNPs were identi-
fied showing differential methylation profiles in each of 
the clusters (Additional file 1: Tables S2 and S3). Overall, 
CII displayed a higher amount of aberrantly methylated 
CpGs (2052 hypermethylated and 390 hypomethylated 
CpGs) when compared to CI (360 hypermethylated and 
66 hypomethylated CpGs). Comparison of these two lists 
of differently methylated CpGs revealed that 97.5  % of 
the CpGs showing aberrant methylation in CI were also 
deregulated in CII. In addition, we identified 691 CpGs 
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Table 1 Patient and tumor characteristics
a Chi squared test
b Mann–Whitney U test
Subtype




Count Proportion Count Proportion Count Proportion
Histological grade
 II 8 1 2 0.5 13 0.76 0.269a 0.316a
 III 0 0 2 0.5 4 0.24
Tumor size
 <1 cm 3 0.375 1 3 10 0.58 0.659a 0.311a
 ≥2 cm 5 0.625 3 8 7 0.42
Node involvement
 Negative 3 0.42 1 0.25 8 0.47 1a 0.603a
 Positive 4 0.58 3 0.75 9 0.53
Ki‑67
 Mean 10 % 50 % 43 % 0.0001b 0.362b
 SD 4 % 22 % 23 %
PgR status
 Negative 0 0 1 0.25 10 0.58 0.008a 0.311a
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Fig. 1 Unsupervised hierarchical clustering of 28 luminal BCs based on 1264 differently methylated CpGs between breast tumors and normal 
breast. The dendrogram was built with the Manhattan distance as dissimilarity metric and the Ward. 2 linkage method for definition of the structure. 
Values on the edges of the clustering are p values (%). Red values on de egde of the clustering are (Approximately Unbiased) p values. AU values 
were computed by multiscale bootstrap resampling. R‑cran “pvclust” package was used for assessing the robustness of these hierarchical clusters 
through multiscale bootstrap resampling of the genes
Page 5 of 10Bediaga et al. SpringerPlus  (2016) 5:623 
containing no known SNPs that were differently methyl-
ated between the two clusters (671 hypermethylated and 
20 hypomethylated CpGs) (Additional file 1: Table S4).
The resulting DNA methylation signatures for the two 
clusters were further analyzed in terms of functionally 
relevant DNA sequence elements. This analysis revealed 
that the distribution of the aberrantly methylated CpGs 
across the different gene annotations (TS1500, proximal 
promoter, body and 3′UTR of the gene) does not dif-
fer significantly between the two clusters and that they 
are not specially enriched for any of the gene locations 
(Fig. 2). In exploring the distribution of the methylation 
events across the CpG islands and their shores in the 
different gene locations, we found that both CI and CII 
involve a higher percentage of methylation event that 
what it was expected in CpG islands and a lower percent-
age in CpG poor regions, but that once more, the distri-
bution of the methylation events across CpG islands was 
very similar between clusters (Fig.  2). We next meas-
ured the extent to which events involving CpG promoter 
methylation were enriched in Polycomb group repressor 
complex 2 (PRC2) target genes in each of the clusters. We 
found out that any of cluster specific signatures were sig-
nificantly enriched as targets of the PCR2 in embryonic 
stem cells (p  <  0.001), but this enrichment was slightly 
higher in CII compared to CI (Fig. 3).
Selection of methylator cluster predictive biomarkers 
and validation of the markers
We next tried to identify CpGs markers that alone or 
in combination with other CpGs could classify luminal 
samples as CI or CII. We identify 25 CpGs among the 691 
differently methylated between the two clusters whose 
cluster predictive power was absolute (Fig. 4a, b). These 
25 markers were further validated in one publicly avail-
able dataset derived from 49 ER positive invasive breast 
carcinomas (GSE31979). Only 24 (5 luminal A, 7 luminal 
B-HER2 and 12 luminal B) of these 49 tumors had com-
plete information about the expression patterns of ER, 
HER2, PgR and Ki-67 by immunohistochemical analysis, 
and thus could be subtyped using the same classification 
used by us (Fackler et  al. 2011). We found that most of 
the selected loci (17 out of 25) followed the same patron 
observed in our discovery set, i.e. luminal A subtype 
showed the lowest methylation levels, luminal B-HER2 
displayed the highest methylation values while luminal B 
tumors were associated with intermediate values (Fig. 5). 
Specifically, there were 3 specific CpGs out of these 17 
(cg17108819, cg13577076 and cg09260089), that showed 
statistically significant differences between luminal A and 
luminal B-HER2 samples but did not show any differ-
ence between luminal Bs and the other two. These three 
CpGs that had almost no methylation overlap between 
the luminal A and luminal B-HER2 subtypes (Fig. 6) were 
further used as subtype predictive biomarkers. For each 
of these 3 CpGs, we measured mean value plus two times 
the standard deviation across the luminal A samples as 




























Fig. 2 Distribution of the differently methylated CpGs across the 
gene annotations. This figure shows that DNA methylation signatures 
for tumors in cluster I and cluster II do not differ significantly with 
respect to the sequence context in which CpG methylation changes 















PRC2 gene targets in promoter regions 
Fig. 3 Percentage of cluster specific methylation events in promoter 
regions analyzed in terms of whether or not they have been identi‑
fied as targets of the Polycomb group repressor complex 2 (PRC2). 
This figure shows that both cluster I and cluster II tumors show a 
higher percentage of PRC2 target genes in promoter regions than 
what expected just by change, being tumors in cluster II the ones 
sowing a higher percentage of PRC2 target genes
Page 6 of 10Bediaga et al. SpringerPlus  (2016) 5:623 
Fig. 4 CpGs with a high cluster predictive power. a, b The 25 CpGs with the highest cluster predictive power
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or Epi-lumA. Based on these classification, 100  % (5/5) 
of the luminal A tumors were classified as Epi-lumA, 
100 % (7/7) of the luminal B-HER2 were classified as Epi-
lumB-HER2 while 58  % (7/12) of the luminal B tumors 
were classified as Epi-lumB-HER2 and 42 % (5/12) as Epi-
lumA. Comparison of the clinic-pathological features of 
the luminal samples clustered in Epi-lumB-HER2 and 
those clustered in Epi-lumA revealed that luminal Epi-
lumB-HER2 presented higher stage (border significance, 
p value 0.1) as well as shorter Disease Free Survival (p 
value <0.05).
Discussion
Luminal B breast tumors have aggressive clinical and bio-
logical features (Creighton 2012). As opposed to luminal 
A tumors, which usually receive endocrine therapy, they 
should be treated with a more aggressive therapy, which 
has not always demonstrated to be effective due to the 
molecular and clinical heterogeneity of this BC subtype 
(Pogue-Geile et  al. 2013). In addition, discordance rates 
between the IHC-based surrogate classification schemes 
proposed so far for the luminal BCs and the multi-gene 
expression assays is still high, and the IHC-based sur-
rogate definition of the luminal B subtype has been sub-
jected to continuous modifications. Thus, identifying a 
surrogate classification scheme that stratifies luminal 
BCs in clinically meaningful subtypes has now became of 
paramount importance in the BC patient management. 
One of the latest and most accepted surrogate definitions 
has been the one proposed in the St Gallen International 
Breast Cancer Conference in 2013, upon which luminal 
A-like tumors are ER+, HER2−, with low Ki-67 expres-
sion (<20 %) and high PgR levels (≥20 %); luminal B-like 
(HER2-negative) tumors are ER+ and HER2− with high 
Ki-67 expression (≥20 %) or low PgR levels (<20 %); and 
luminal B-HER2 tumors are ER+ and HER2+, regardless 
PgR or Ki-67 expression. However, this new definition 
has already been questioned by some authors (Maison-
neuve et al. 2014) and the surrogate definition is expected 
to be under further modifications. In this respect, we 
believe that a better characterization of the molecular 
alterations associated with of each of these new surro-
gate definitions would improve our understanding of the 
luminal tumor phenotype and led to a continuous refine-
ment of the molecular classification of the BC.
From the epigenetic point of view, previous studies 
have documented that specific DNA methylation pat-
terns can be related to some different luminal subtypes 
(Dedeurwaerder et  al. 2011; Bediaga et  al. 2010; Holm 
et  al. 2010; Stefansson et  al. 2015; Cornen et  al. 2014; 
Li et al. 2014; Kamalakaran et al. 2011; Fang et al. 2011; 
Conway et  al. 2014; Van der Auwera et  al. 2010; Flana-
gan et al. 2010). Specifically, luminal B cancers have been 
usually associated with a methylator phenotype charac-
terized by an extent DNA methylation in CpG islands 
(Bediaga et  al. 2010; Holm et  al. 2010; Stefansson et  al. 
2015). On the contrary, luminal A tumors have been 
described as being more heterogeneous in terms of their 
methylation patterns and with less methylation changes 
with respect to the normal (Bediaga et al. 2010; Stefans-
son et al. 2015). Aware of the biologic/epigenetic hetero-
geneity within luminal subgroup, we have compared for 
the first time the DNA methylation profiles associated 
the newly proposed IHC-based surrogate definition of 
the luminal B and compared it to that of the luminal A 
and B-HER2, thus providing new insights into the molec-
ular features of the luminal B BCs. Our results, based 
on the unsupervised clustering of the luminal BC sam-






































Fig. 5 Methylation levels of the 17 CpGs with the highest cluster 
predictive power in the validation set (GSE31979). As in the discovery 
set Luminal A subtype showed the lowest methylation levels, luminal 
B‑HER2 displayed the highest methylation values while luminal B 
tumors were associated with intermediate values
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Sixty-two percent of the luminal B samples were grouped 
in cluster I (CI) together with luminal A tumors, while 
approximately third of the luminal B samples was clus-
tered in cluster II (CII), which showed a higher propor-
tion of methylation events and grouped the whole set of 
luminal B-HER2. Interestingly, tumors in CII were signif-
icantly bigger, had higher proliferative activity and worse 
outcome than those at CI. Further functional analysis 
of the epigenetic signatures associated with each of the 
two clusters indicated that distribution of the aberrant 
CpGs across the different gene annotations does not dif-
fer significantly for each cluster. On the other hand, when 
we investigated the extent to which genes with cluster 
specific methylation patterns were also PRC2 targets 
in ES cells, we found that both aberrant DNA methyla-
tion patrons in CI and CII were significantly enriched in 
PRC2 gene targets (i.e. they had a higher proportion of 
PRC2 than what is it expected), although CII showed a 
slightly higher enrichment in PRC2 target genes com-
pared to tumors in CI. Finally, comparison of these two 
epigenetic signatures also revealed an extent overlap in 
the aberrantly methylated genes between the two cluster, 
i.e. 97.5 % of the CpGs showing aberrant methylation in 
CI were also deregulated in CII. Taken all together, our 
results indicated that (1) based on the St. Gallen IHC 
classification system, luminal B phenotype itself does 
not show a distinctive DNA methylation pattern (signifi-
cant at AU > 95 %; by the pvclust method) but rather an 
heterogeneous methylation signature where 62  % of the 
samples clustered with luminal A and 30 % with the lumi-
nal B-HER2; (2) DNA methylation profiles enable the 
stratification of luminal B samples in two categories with 
differing epigenetic and clinical features, thus suggest-
ing that adding certain epigenetic markers to the latest 
St. Gallen IHC classification scheme could improve the 
clinical relevance of the surrogate scheme; and (3) lumi-
nal B cancers have significantly greater numbers of meth-
ylation events than the luminal A, but methylation events 
in luminal A are present in luminal B, besides distribu-
tion of the methylation events across gene annotations 
is similar which all together may support the hypothesis 
that luminal B cancer precursors evolve from luminal A 
cancer/cancer precursors as has been previously specu-
lated in Creighton et al. (2012).
A growing number of studies have identified gene 
hypermethylation profiles in subsets of luminal breast 
Fig. 6 Boxplots of methylation levels of the three markers in the model in the validation set (GSE31979)
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tumors (ER+) (Bediaga et  al. 2010; Holm et  al. 2010; 
Stefansson et al. 2015; Conway et al. 2014) and some of 
them have been independently associated with poorer 
clinical outcomes (Conway et al. 2014). Holm et al. (2010) 
described a signature of 196 CpGs that were found to be 
more frequently methylated in what they called lumB 
methylator phenotype. Bediaga et  al. (2010) also identi-
fied a highly methylated luminal subtype characterized by 
the hypermethylation of a number of genes. On the other 
hand, Conway et  al. (2014) reported four methylation-
defined tumor clusters within the BC samples studied, 
among which cluster 3 (specially enriched in mRNA-sub-
type-luminal Bs) exhibited the highest methylation levels 
and worse long-term survival. Stefansson et  al. (2015) 
also defined two DNA methylation-based subtypes, 
among which the Epi-LumB displayed a clear tendency 
to display CpG island promoter methylation events that 
was associated with unfavorable clinical parameters and 
reduced survival. Comparison of the above mentioned 
methylator signatures and the one described in the cur-
rent study revealed that there is relatively high overlap 
and that there was a significant number of genes that 
were consistently deregulated (Additional file  1: Table 
S5), thus further supporting the existence of a luminal B 
methylator phenotype within the luminal B and luminal 
B-HER2 BCs.
In an attempt to create an epigenetic model that could 
characterize the luminal methylator phenotype described 
herein, we selected 25 CpG markers whose cluster predic-
tion power was complete. We further analyzed the DNA 
methylation pattern of these 25 CpGs in an independent 
set of the luminal A, luminal B and luminal B-HER2 sam-
ples included in the GSE31979 study (Fackler et al. 2011) 
and found that most of them showed the same methyla-
tion patterns observed by us, i.e. high methylation levels 
in luminal B-HER2 and significantly lower ones in lumi-
nal A, with dispersed DNA methylation values in luminal 
Bs. Specifically, a methylation panel based on three CpGs 
(cg17108819, cg13577076 and cg09260089) grouped the 
entire set of luminal A samples as Epi-lumA and all the 
luminal B-HER2s as Epi-lumB-HER2. With respect to the 
luminal B tumors, 58 % of the luminal Bs were clustered 
with the luminal B-HER2 (i.e. displayed the luminal B 
methylator phenotype) while only 42 % were grouped with 
the luminal A. Further analysis of the clinical characteris-
tics of the tumors displaying the luminal methylator phe-
notype revealed that these new DNA methylation subtype 
could be clinically relevant as indicated by their higher 
stage and worse outcome compared to those without the 
methylator phenotype. However, we note that the prog-
nostic relevance of the methylator signature needs still 
to be further validated in independent and much larger 
luminal BC samples. On the other hand, it has recently 
been reported that some of the HER2-negative tumors 
could benefit from anti-HER2 therapy treatment (Pogue-
Geile et al. 2013), thus it would be also interesting to know 
whether those luminal B-HER2 negative showing a meth-
ylator phenotype and similar epigenetic features to luminal 
B-HER2 respond to anti-HER2 therapy treatment.
Conclusions
This work demonstrates that DNA methylation profiles 
enable the stratification of luminal B samples in two cat-
egories with differing epigenetic and clinical features. 
Specifically, a methylation panel based on three CpGs 
separates the entire set of luminal A samples from the 
luminal B-HER2s, and divides luminal B tumors in two 
groups clustering with luminal A and luminal B-HER2, 
respectively, suggesting that adding certain epige-
netic markers to the latest St. Gallen IHC classification 
scheme could improve the clinical relevance of the sur-
rogate scheme with respect to management of luminal B 
tumors.
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